Skip to content

Study · Measured the body's own peptide · 1994

7 results

Plasma zinc level and thymic hormone activity in young cancer patients.

Mocchegiani E, Paolucci P, Granchi D, Cavallazzi L, Santarelli L, Fabris N

Blood1 Feb 1994Cited by 18 (Europe PMC)

PMID8298137 (opens in a new tab)DOI10.1182/blood.v83.3.749.749 (opens in a new tab)PepBankPUB-08298137
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Natural levels measured7

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In young patients with ALL, total zinc-saturable thymulin concentration did not change across disease stages.

    In plain wordsIn young patients with ALL, total levels of the body's own zinc-saturable thymulin did not change across disease stages.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeTotal zinc-saturable thymulin concentration
    Study

    n: not reported in source

    Comparator
    other disease stages
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Total zinc-saturable thymulin concentration did not change during the disease
    1 context sentence
    Summary · context
    we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In young patients with ALL, active plasma thymulin was lower at disease onset than at other disease stages.

    In plain wordsIn young patients with ALL, the body's own active thymulin was lower at onset than at other disease stages.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseActive thymulin at disease onset
    Study

    n: not reported in source

    Comparator
    other disease stages
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls.
    1 context sentence
    Summary · context
    we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In young patients with ALL, active plasma thymulin was lower at disease onset than in healthy controls.

    In plain wordsIn young patients with ALL, the body's own active thymulin was lower at onset than in healthy controls.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseActive thymulin at disease onset versus healthy controls
    Study

    n: not reported in source

    Comparator
    healthy controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls.
    1 context sentence
    Summary · context
    we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In young patients with ALL, active plasma thymulin was lower at relapse than at other disease stages.

    In plain wordsIn young patients with ALL, the body's own active thymulin was lower at relapse than at other disease stages.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseActive thymulin at relapse
    Study

    n: not reported in source

    Comparator
    other disease stages
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls.
    1 context sentence
    Summary · context
    we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    In young patients with ALL, active plasma thymulin was lower at relapse than in healthy controls.

    In plain wordsIn young patients with ALL, the body's own active thymulin was lower at relapse than in healthy controls.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseActive thymulin at relapse versus healthy controls
    Study

    n: not reported in source

    Comparator
    healthy controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls.
    1 context sentence
    Summary · context
    we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelObservational studyOther

    In young patients with ALL, active thymulin positively correlated with peripheral immunological parameters measured using PHA at various disease stages.

    In plain wordsIn young patients with ALL, the body's own active thymulin was positively linked to immune responses measured using PHA.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseActive thymulin correlation with PHA immunological response
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The existence of positive correlations between zinc or active thymulin and peripheral immunological parameters (phytohemagglutinin [PHA] and concanavalin A [ConA]) at various stages of the disease
    1 context sentence
    Summary · context
    we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

  7. 07HumanEndogenous levelObservational studyOther

    In young patients with ALL, active thymulin positively correlated with peripheral immunological parameters measured using ConA at various disease stages.

    In plain wordsIn young patients with ALL, the body's own active thymulin was positively linked to immune responses measured using ConA.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseActive thymulin correlation with ConA immunological response
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The existence of positive correlations between zinc or active thymulin and peripheral immunological parameters (phytohemagglutinin [PHA] and concanavalin A [ConA]) at various stages of the disease
    1 context sentence
    Summary · context
    we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.